A key advisory panel for the Centers for Disease Control and Prevention (CDC) has updated its guidance on a common childhood vaccine, recommending that the combination measles-mumps-rubella-varicella (MMRV) shot not be given to children under the age of 4.
The Advisory Committee on Immunization Practices (ACIP) voted 11-1 on Thursday to recommend that young children instead receive separate shots for measles, mumps, and rubella (MMR) and chickenpox (varicella). The decision, which is not yet final, is based on a small but well-established increased risk of febrile seizures in the youngest patients following the combination vaccine.
Understanding the Risk
Febrile seizures are convulsions triggered by a fever and are most common in children between 6 months and 5 years old. While frightening to witness, they are typically brief and do not cause long-term health problems.
The CDC’s data, presented at the meeting, confirms a known but minimal risk: for every 2,300 to 3,200 children under age 4 who receive the first dose of the MMRV vaccine instead of separate MMR and varicella shots, one additional febrile seizure may occur. This risk is not associated with the second dose, given at ages 4-6, or with the separate MMR and varicella vaccines.
What This Means for Parents
The vote does not change the overall childhood vaccination schedule. Children still need two doses of the measles, mumps, and rubella (MMR) vaccine and two doses of the varicella (chickenpox) vaccine.
First dose (ages 12-15 months): The ACIP now recommends these be given as two separate shots (MMR and varicella).
Second dose (ages 4-6 years): Parents can choose either the combination MMRV shot or two separate shots, as there is no increased seizure risk at this age.
The vast majority of parents (approximately 85%) already opt for the separate shots for their child’s first dose, according to CDC data.
Next Steps and Context
The committee’s recommendation will now be reviewed by the acting CDC director for final approval. The Department of Health and Human Services stated it will “examine all insurance coverage implications” before a final decision is made.
This meeting was the first for five new members recently appointed to the 12-person committee. The shake-up has drawn scrutiny from public health experts, who note that some new members have previously expressed skepticism toward vaccines. However, the data presented on the MMRV vaccine was not new and simply reinforced a risk that pediatricians have managed for years.
“The real question isn’t whether MMRV’s small seizure risk justifies offering separate shots—we already do that,” said Dr. Jake Scott, an infectious disease specialist at Stanford University, in a prior interview. He and other experts worry that revisiting long-settled science could unnecessarily erode public trust in vaccines that are proven to be safe and vital for public health.
The ACIP is scheduled to discuss other topics, including the hepatitis B vaccine and updated COVID-19 boosters, in its ongoing meeting.
YOU MAY ALSO LIKE
Light Therapy Lamp Innovations: YouLumi IRP010 Series for Wellness
Probiotics in Neonatal Care: The Next Frontier in Infant Health
Mayo Clinic Develops Genetic Test to Predict Weight-Loss Drug Success
